Pharmaceutical Interventions
-
1.1KTopical Low-Dose Atropine: A Global Perspective
-
1.6KEyenovia Developing a Microdose Treatment for Delivering Atropine
-
3.6KOne Drop into Each Eye at Bedtime: What Could be Simpler?
-
1.1KWhat is the Optimal Concentration of Topical Low-dose Atropine?
-
4.8KRecommendations for Tapering Long-term Use of Topical Low-dose Atropine
There are two strategies to consider for stopping atropine treatment.
-
2.2KCochrane Systematic Review of Myopia Interventions
-
7.8KCombination Strategies – What is Their Role in Myopia Management?
Individual interventions may not result in the expected efficacy.
-
Interventions for Controlling Myopia Onset and Progression Report
-
1.4KWhat’s New with Pharmaceutical Interventions for Myopia
Presently, only atropine, pirenzepine, and 7-methylxanthine are shown to reduce myopia progression in human trials.
-
4.4KEfficacy and Safety of 0.01% Atropine in Myopic Children With European Ancestry
The researchers concluded that topical low-dose atropine appears to be safe and effective in a cohort of European schoolchildren.
-
2.1K
Low-Concentration Atropine for Myopia Progression (LAMP)
A summary of the LAMP Study results
-
1.2KOrthokeratology, low-dose atropine and axial elongation
Axial elongation rate is faster in younger children undergoing ortho-k treatment.
-
4.2K
Topical Atropine for Myopia Management: The Latest Research
When should one start atropine treatment for myopes?
